Publications

研究人員近期研究主題一覽表

 Neurodegeneration Group 

Dr. Yun Wang
  1.  Endoplasmic reticulum stress in stroke and methamphetamine toxicity
  2. Repositioning anti-diabetics for Parkinson’s disease (PD) and traumatic brain injury (TBI) (PT320 and PD; PT320 and L-dopa-induced dyskinesia; Gliptins and PD; and Gliptins and TBI)
  3.  Cell therapy for stroke and PD (neuroprotective action of human Wharton’s jelly-derived mesenchymal stromal cell transplants in a rodent model of stroke; NanoCsA improves the survival of human iPSC transplant in hemiparkinsonian rats)
  4.  Gene therapy for PD disease (downregulation of alpha-synuclein protein levels by an intracellular single-chain antibody; administration of AAV-alpha synuclein NAC antibody improves locomotor behavior in rats overexpressing alpha-synuclein)
  5. Recombinant adeno-associated virus-mediated expression of methamphetamine antibody attenuates methamphetamine response
  6. New CXCR4 drug development for the treatment of hemorrhagic stroke
Dr. Feng-Shiun Shie
  1. Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity
  2. Development of a novel anti-oligomeric Ab antibody for Alzheimer’s disease therapy
  3. Synergistic effects of combining the curcumin analogue TML-6 and low-dose anti-amyloid-β antibody in APP/PS1 mice
  4. The development of in vitro and in vivo early diagnosis of dementia
Dr. Wen-Hai Chou
  1. Neutralization of lipocalin-2 diminishes stroke-reperfusion injury
  2. Genetic inhibition of PKCε attenuates neurodegeneration after global cerebral ischemia in male mice
  3.  PKCε phosphorylation regulates the mitochondrial translocation of ATF2 in ischemia-induced neurodegeneration
  4.  Lipocalin-2 mediates the rejection of neural transplants
Dr. Seong-Jin Yu
  1.  Neuroprotection against acute stroke or TBI (neuroprotection induced by human milk oligosaccharide after acute ischemic stroke; neuroprotection induced by human milk oligosaccharide against acute hemorrhage stroke; neuroprotection induced by a novel anti-inflammatory agent CX807 for acute hemorrhage stroke; neuroprotection through anti-inflammation through repositioning naltrexone after acute TBI; neuroprotection through repositioning acetyl cholinerestase inhibitor phenserine after acute ischemic stroke injury)
  2.  Experimental therapy for subacute and chronic stroke (Post-treatment with 2’-FL for the subacute/chronic stroke; stem cell therapy for subacute/chronic stroke)
  3. Collaborative research in PD (stem cell therapy for PD; pharmacological therapy for PD; antibody therapy for PD)

Psychiatric and Addiction Group

Dr. Wei J. Chen
  1.  Blood-based biomarkers as diagnostics or theranostics for schizophrenia: a multi-omics approach (polygenic risk score and symptomatology, severity, and response to antipsychotics during first- episode psychosis; DNA methylation in peripheral blood cells is correlated with symptomatology, severity, and response to antipsychotics during first- episode psychosis; blood-based expression levels of miRNAs and symptomatology, severity, and response to antipsychotics during first-episode psychosis; and whether a combination of schizophrenia PRS, DNA methylation, and miRNAs improve the diagnostic discrimination as well as the prediction of treatment response)
  2. Psychotic Inpatients Cohort in Taiwan (PICT) (to recruit a total of 1000 cases of eligible psychotic inpatients from psychiatric departments in various hospitals by the end of the four-year study)
Dr. Hwei-Hsien Chen
  1. Development of novel medicine for club drug–induced psychological dependence, psychiatric disorders and neurodegeneration
  2. he neurobiology of ketamine reinforcement
  3. Developing NMDA receptor modulators for treatment of ketamine addiction and related cognitive deficits
Dr. Yu-Li Liu
  1.  Methadone dosage regulatory mechanism search
  2.  Neurotoxicity of ketamine abuse
  3.  Stroke-induced neurodegenerative disease, particularly post stroke dementia
Dr. Sheng-Chang Wang
  1.  Clinical features of community drug users in Taiwan (suicidality among community ketamine ever users in Taiwan; sleep quality and internet use among community ketamine users; neurobiological and neurocognitive biomarkers of drug use disorders; pharmacogenomics of methadone treatment for heroin dependence)
  2.  Using big data analytics in drug use problems in Taiwan (outcomes of heroin users with experience of methadone maintenance treatment)
  3.  Development of the evidence-based addiction treatment models (developing the culturally-adapted models for addiction treatment in Taiwan; implementing the evidence-based addiction treatment programs)
  4. Translational research projects on addiction treatment practice and policy (improving quality of services for methadone clinics- promoting methadone guest-dosing, point-of-care urine drug testing and suicide prevention; and enquiring the addiction treatment system in the Ministry of Justice-affiliated detention centers)
Dr. Yen-Feng Lin
  1. Methamphetamine use disorder (prognosis-associated factors of coerced addiction treatment for methamphetamine users; a genome-wide polygenic approach to methamphetamine use and methamphetamine-induced psychosis: genetic etiology, cross-trait polygenic overlap, and potential causal relationships)
  2.  Phenome-wide genome-wide analysis of complex phenotypes in Taiwanese population
Dr. Chuan-Yu Chen
  1. Children of addicted parents: unmet needs in healthcare and social services (ended at the end of 2020),
  2. Scheduled III and IV drugs-involved young people: unmet needs in health and social car (2021/01-), which will be described below in terms of rationales and methodology.
Dr. Tsuo-Hung Lan
  1. Taiwan health insurance claim data analysis
  2. Neurodegenerative disorder in elderly
  3. Smoking cessation program in women and elderly

Training Office for Addiction Treatment Professionals

Dr. Wei J. Chen
   Fostering addiction treatment and intervention professionals:

  1.  translating “Universal Treatment Curriculum (UTC) for Substance Use Disorders” into Chinese and to establish localized Taiwanese version of the training materials;
  2. providing needed training for non-physician primary workers in addiction treatment and intervention in different stages;
  3. advocating “Clinical and Research Dual Fellowship in Addiction”

Update 2021-09-09


 

 2,468 total views,  2 views today

Comments are closed.